“…In this month's issue, we include three exciting editor's choice studies. The first, by da Silva et al, 1 discusses how hypoallergenic derivatives of Blo t21, a storage and house dust mite, may possess immunomodulatory properties and may serve as a candidate for a safer allergen immunotherapy. Conventional allergen immunotherapy using crude allergen extracts can be effective in treating allergies, 2,3 however, there are also some challenges.…”